ADVIL COLD AND SINUS Drug Patent Profile

Which patents cover Advil Cold And Sinus, and what generic alternatives are available?

Advil Cold And Sinus is a drug marketed by Haleon Us Holdings and is included in two NDAs.

The generic ingredient in ADVIL COLD AND SINUS is ibuprofen; pseudoephedrine hydrochloride. There are sixty-four drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ibuprofen; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advil Cold And Sinus

A generic version of ADVIL COLD AND SINUS was approved as ibuprofen; pseudoephedrine hydrochloride by STRIDES PHARMA on August 14^th, 2006.

Summary for ADVIL COLD AND SINUS

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for ADVIL COLD AND SINUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ADVIL COLD AND SINUS	ibuprofen; pseudoephedrine hydrochloride	CAPSULE;ORAL	021374-001	May 30, 2002		OTC	Yes	Yes
Haleon Us Holdings	ADVIL COLD AND SINUS	ibuprofen; pseudoephedrine hydrochloride	TABLET;ORAL	019771-001	Sep 19, 1989		OTC	Yes	Yes

International Patents for ADVIL COLD AND SINUS

See the table below for patents covering ADVIL COLD AND SINUS around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	222586	A SOLVENT SYSTEM ENHANCING THE SOLUBILITY OF PHARMACEUTICALS FOR ENCAPSULATION
Japan	H07116021
Japan	H08157355	AMPHOTERIC PHARMACEUTICAL SOLUTION FOR SOFT GEL FILLING, TWO-PIECE CAPSULE SEALING OR TABLET MANUFACTURING
European Patent Office	0180597	COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Canada	1316823	PREPARATION DE CERTAINS MEDICAMENTS EN VUE DE FAVORISER LEUR ENCAPSULATION (FACILITATION OF CERTAIN DRUGS FOR CAPSULATION)
South Korea	940008030
South Africa	8802884

Advil Cold and Sinus: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

This report provides a comprehensive analysis of Advil Cold and Sinus, focusing on its market positioning, competitive landscape, investment potential, and financial outlook. As a leading OTC (over-the-counter) medication in the cold and sinus relief segment, Advil Cold and Sinus benefits from the Coca-Cola-backed consumer healthcare portfolio and strong brand recognition. However, market dynamics, regulatory environment, and evolving consumer preferences influence its growth trajectory.

---

1. Product Overview and Market Positioning

Product Name	Advil Cold and Sinus
Active Ingredients	Ibuprofen, pseudoephedrine (usually)
Form	Tablets, caplets
Indications	Cold, sinus pressure, congestion relief
Manufacturer	Johnson & Johnson (Johnson & Johnson Consumer Inc.)

Market positioning: Advil Cold and Sinus is positioned as a premium OTC medication targeting consumers seeking fast-acting, multi-symptom relief. It's part of Johnson & Johnson’s (J&J) expansive OTC portfolio, capitalizing on its trusted brand name and manufacturing capabilities.

---

2. Market Dynamics

A. Industry Size and Growth

Segment	Market Size (USD billions)	Growth Rate (CAGR 2022-2027)	Notes
OTC Cold & Flu Remedies	$18.5 billion	4.3%	Driven by aging population, urbanization
Sinus & Nasal Medications	$4.2 billion	3.8%	Increasing preference for OTC solutions

Sources: IBISWorld, MarketResearch.com (2022)

B. Consumer Behavior

• Preference for OTC medications over prescription drugs increases accessibility and convenience.
• Growing demand for multi-symptom formulations due to busy lifestyles.
• Shift toward natural and "clean-label" products impacting formulation choices.

C. Regulatory Environment

• Regulatory oversight by FDA in the U.S. influences formulation, marketing, and packaging.
• Pseudoephedrine sales are tracked to prevent misuse, impacting OTC availability.
• New regulations may restrict sales or impose reformulation requirements.

D. Competitive Landscape

Major Competitors	Key Products	Market Share (approx.)	Strengths
Pfizer	Sudafed, Advil, Theraflu	30%	Strong branding, extensive R&D
Bayer	Aleve, Claritin	20%	Diversification, global presence
Reckitt Benckiser	Lemsip, Nurofen	15%	Innovation, regional focus
Johnson & Johnson (Adv. Line)	Tylenol, Advil Cold and Sinus	25%	Brand trust, distribution network

Note: Advil Cold and Sinus competes directly with Sudafed from Pfizer, Equate Sinus & Cold, and store brands.

---

3. Financial Trajectory and Investment Outlook

A. Revenue & Market Share Trends

Year	Estimated Sales (USD millions)	Growth Rate	Commentary
2020	$450	-	Peak due to COVID-19-driven demand
2021	$475	5.6%	Moderate growth, stabilization post-pandemic
2022	$500	5.3%	Continued steady growth
2023	$525	5%	Slight acceleration with new marketing campaigns
2024-2027	CAGR of 4-6%	Stability	Projected, driven by aging demographics and product innovations

Note: These are estimations based on industry trends and past sales data.

B. Profitability and Margins

Parameter	Estimate (2022)	Remarks
Gross Margin	60-65%	Manufacturing efficiencies, brand premium
Operating Margin	25-30%	Marketing and distribution costs
R&D Investment	~2-3% of sales	Limited, mainly reformulation or new variants

C. Regulatory and Patent Considerations

• Patent expirations can influence pricing and generic competition.
• Advil Cold and Sinus formulations may face patent cliffs within 5 years.
• Regulatory amendments or safety concerns can impact sales growth.

D. Investment Potential

Factor	Assessment	Implication
Market Size & Growth	Stable and growing segment	Positive for sustained revenues
Competitive Landscape	High competition but entrenched brands exist	Challenges to market share expansion
Brand Strength	Strong, trusted brand	Buffer against generic competition
Regulatory Environment	Tight controls, but predictable	Risks manageable with proper compliance
Innovation & Formulation Advances	Incremental, due to OTC constraints	Limited growth contribution from innovation

Summary: Advil Cold and Sinus holds a stable, moderately growing position, with a forecasted CAGR of 4–6% through 2027. Its financial outlook remains strong amid competitive pressures, provided regulatory compliance and innovation strategies are maintained.

---

4. Comparative Analysis: Advil Cold and Sinus vs. Key Competitors

Criteria	Advil Cold and Sinus	Sudafed (Pfizer)	NasalSpray (Nasonex)	Store Brands
Brand Recognition	High	Very High	Moderate	Low
Pricing Range	Premium	Premium	Mid-range	Low
Product Formulation	Multi-symptom OTC	Decongestant focus	Nasal spray	Various
Regulatory Challenges	Pseudoephedrine limits	Pseudoephedrine limits	OTC regulation rules	None
Innovation Capacity	Incremental	Incremental	Moderate (delivery mechanisms)	Varies
Consumer Loyalty	Strong	Very Strong	Moderate	Varies

---

5. Strategic Outlook and Opportunities

Opportunity	Description
Product Line Extensions	New formulations targeting different symptoms or natural variants
Geographic Expansion	Developing markets (e.g., Asia-Pacific, Latin America)
Digital Marketing & E-commerce	Engaging direct-to-consumer channels
Regulatory Navigation	Anticipate and adapt to evolving policies
Acquisition & Partnerships	Collaborations with biotech firms for novel delivery systems

---

6. Risks and Challenges

Risk	Impact	Mitigation Strategies
Regulatory Changes	Reclassification or sales restrictions	Active compliance, lobbying efforts
Patent Expiry & Generics	Price erosion, margin pressure	Brand reinforcement, innovation
Consumer Preference Shift	Preference for natural/no-pill remedies	Formulation diversification
Supply Chain Disruption	Production delays, cost increases	Diversify suppliers, inventory buffer
Market Saturation	Diminishing growth prospects	Market expansion, new product categories

---

7. Key Takeaways

• Advil Cold and Sinus remains a resilient OTC product with steady revenue streams.
• Its market position is reinforced by brand trust, but faces challenges from patent expiries and competing formulations.
• The segment's CAGR of 4–6% indicates moderate growth opportunities, primarily through innovation and geographic expansion.
• Regulatory landscape remains a key factor, with pseudoephedrine sales restrictions influencing formulations.
• Strategic investments should prioritize product innovation, digital marketing, and expansion into emerging markets.

---

8. Frequently Asked Questions (FAQs)

Q1. How significant is the impact of patent cliffs on Advil Cold and Sinus?
Patents for formulations typically expire within 5 years post-launch, exposing the product to generic competition. While this can erode margins and market share, brand strength and consumer loyalty mitigate some risks. Strategic reformulation and new variants can offset patent expirations.

Q2. What are the key regulatory considerations for OTC cold medications?
Regulations focus on safety, efficacy, and ingredient transparency. Pseudoephedrine sales are monitored to prevent misuse, and any reformulation must meet FDA standards. Changes in OTC classifications or ingredient restrictions could impact product availability.

Q3. How does consumer preference shift toward natural remedies affect Advil Cold and Sinus?
The trend toward natural products may reduce OTC formulations' appeal. To counteract this, J&J is investing in natural and alternative formulations and marketing strategies emphasizing trusted efficacy.

Q4. What growth opportunities exist in emerging markets?
Rapid urbanization, increasing middle-class populations, and limited healthcare infrastructure create opportunities. Customizing formulations, pricing, and distribution can capitalize on these markets.

Q5. How does innovation influence the future trajectory of Advil Cold and Sinus?
Innovation in delivery mechanisms (e.g., nasal sprays, dissolvable tablets), natural ingredients, and multi-symptom formulations can sustain relevance and drive growth, especially among younger consumers seeking alternatives.

---

References

[1] IBISWorld, OTC Cold & Flu Market Report (2022).
[2] MarketResearch.com, Sinus & Nasal Medications Industry Analysis (2022).
[3] Johnson & Johnson Annual Report 2022.
[4] FDA Regulations on OTC Medications (2022).
[5] Consumer Trends in OTC Pharmaceuticals, GlobalData (2022).